Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company founded in 2020 and based in Boulder, Colorado. The company went public on March 12, 2020, and focuses on discovering and developing small molecule inhibitors designed to treat various forms of cancer. As a clinical-stage biotech company, Enliven is currently advancing multiple drug candidates through early-phase clinical trials, with no approved products or revenue to date.

Based on the available financial data, Enliven Therapeutics has been primarily focused on advancing its two key clinical programs through Phase 1 trials. The company has maintained consistent investment in research and development, with operating cash flow burns ranging from $12-24 million per quarter, indicating steady clinical trial activity and operational expansion. The company's cash position has remained relatively stable, suggesting successful capital raising activities to fund ongoing operations. The increase in total assets from $271.9 million in FY 2023 to $325.8 million in FY 2024 indicates continued investment in the business and possibly additional funding rounds to support clinical development activities. Operational scaling is evident from the increasing quarterly losses and cash burn rates, which typically reflects expanded clinical trial activities, additional patient enrollment, and growing operational infrastructure needed to support multiple concurrent drug development programs. The company appears to be in the critical phase of generating clinical data that will determine the future viability of both ELVN-001 and ELVN-002 programs.